

**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE**

International Application No. : PCT/EP2004/007224  
International Filing Date : 02 July 2004 (02.07.2004)  
Priority Date(s) Claimed : 30 July 2003 (30.07.2003)  
Applicant(s) (DO/EO/US) : Guenter HOELZEMANN, et al.

Title: UREA DERIVATIVES AND THE USE THEREOF AS INHIBITORS OF TYROSINE KINASES

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

**Timing and Fees**

- Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
  - within three months of the filing date of a national application other than a CPA under § 1.53(d);
  - within three months of the actual filing date of the national phase of a PCT application; OR
  - before the mailing of a first substantive office action (including after filing of an RCE).
- Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
  - a final rejection under 37 C.F.R. 1.113;
  - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2); OR
  - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

IAP5 Rec'd PCT/PTO 30 JAN 2006

the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR

a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:

a final action under 37 C.F.R. § 1.113;

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2);

OR a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

#### Statements Under 37 C.F.R. 1.97(e)

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

#### Cited Materials

Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. \_\_\_\_\_, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).

Copies of materials listed but not attached were cited in an international search report dated November 12, 2004.

Not required by 37 CFR § 1.98.

Copies of the materials listed are attached (only of WO 00/42012).

Non-English Language References

An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).

A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone

Y = document of particular relevance when it is combined with another such document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

Translation of other relevant information on foreign search report

In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispiele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwähnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abbildung" means figure.

Other InformationPayment of Fees Due (If Any):

A check for \$\_\_\_\_\_ covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$\_\_\_\_\_ for the fee identified above.

10/566351

IAP5 Rec'd PCT/PTO 30 JAN 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

  
Anthony J. Zelano, Reg. No. 27,969  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3114

Date: January 30, 2006

AJZ:ssr

IAP5 Rec'd PCT/PTO 30 JAN 2006

10/566351

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002 OMB 0651-0031

Approved for use through 10/31/2002. OMB 0851-0031  
**U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**  
respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 1 of 1

**Complete if Known**

Application Number	USNP of PCT/EP2004/007224
Filing Date	02 July 2004 (02.07.2004)
First Named Inventor	Guenter HOELZEMANN, et al.
Group Art Unit	unknown
Examiner Name	unknown
Attorney Docket Number	MERCK-3114

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	001	WO	00/42012	A1	BAYER CORPORATION	07-20-2000	
	002	WO	03/099771	A2	NOVARTIS A.-G., SWITZ; NOVARTIS PHARMA GMBH	12-04-2003	
	003	WO	02/44156	A2	GLAXO GROUP LTD	06-06-2002	
	004	WO	02/062763	A	RIEGL, ET AL.	08-15-2002	
	005	WO	99/32436	A	BAYER AG	07-01-1999	
	006	WO	03/047523	A2	ONYX PHARM. INC.	06-12-2003	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.